Influence of ipilimumab on expanded tumour derived T cells from patients with metastatic melanoma.

ABSTRACT:

Introduction

Tumour infiltrating lymphocyte (TIL) based adoptive cell therapy (ACT) is a promising treatment for patients with advanced melanoma. Retrospective studies suggested an association between previous treatment with anti-CTLA-4 antibodies and long term survival after subsequent ACT. Thus, we hypothesized that treatment with anti-CTLA-4 antibodies can induce favourable changes to be detected in TILs.

Results

Expanded T cells from Ipilimumab treated patients had a higher proportion of cells expressing CD27, intracellular CTLA-4, TIM-3 and LAG-3. In addition, broader and more frequent T cell responses against common tumour antigens were detected in patients treated with Ipilimumab as compared to anti-CTLA-4 naïve patients.

Materials and methods

Expanded TILs wer

SUBMITTER: Bjoern J 

PROVIDER: S-EPMC5432318 | biostudies-literature | 2017 Apr

REPOSITORIES: biostudies-literature